Welcome to our dedicated page for Sana Biotechnology news (Ticker: SANA), a resource for investors and traders seeking the latest updates and insights on Sana Biotechnology stock.
Sana Biotechnology, Inc. (NASDAQ: SANA) is a biotechnology company focused on creating and delivering engineered cells as medicines, and its news flow reflects this emphasis on cell and gene-based therapies. Company press releases and updates describe progress across its hypoimmune platform for allogeneic cell therapies and its fusogen platform for in vivo delivery of genetic payloads.
Investors following SANA news can read about clinical and preclinical milestones in type 1 diabetes, B-cell cancers, and B-cell–mediated autoimmune diseases. Sana has reported investigator-sponsored clinical data for UP421, a primary human pancreatic islet cell therapy engineered with hypoimmune technology, including results showing survival and function of transplanted beta cells without immunosuppression. News items also cover development of SC451, an O-negative, HIP-modified, iPSC-derived pancreatic islet cell therapy, and in vivo CAR T candidates such as SG299 and SG293 built on the fusogen platform.
In addition to scientific and clinical updates, Sana’s news includes quarterly financial results, portfolio prioritization decisions, and capital-raising activities through public offerings and at-the-market equity programs. The company also issues announcements about participation in healthcare and investor conferences, where management provides business overviews and program updates.
This news page aggregates these disclosures so readers can monitor developments in Sana’s engineered cell programs, regulatory interactions, scientific publications, and financing events associated with the SANA stock. For investors and observers of the biotechnology sector, the SANA news stream offers insight into how the company is advancing its platforms and concentrating resources on type 1 diabetes and in vivo CAR T approaches.
Sana Biotechnology (NASDAQ: SANA) reported its Q1 2022 results, revealing a cash position of $657.4 million as of March 31, down from $746.9 million at the end of 2021. Notable research and development expenses surged to $72.7 million, influenced by increased personnel and manufacturing costs. The net loss narrowed to $31.4 million, or $0.17 per share, compared to $180.6 million in Q1 2021. The company plans to file INDs for its ex vivo and in vivo CAR T programs this year. Additionally, strong conference presentations are scheduled for 2022, highlighting ongoing advancements.
Cellarity has appointed Dr. Sandra Horning to its Board of Directors. Dr. Horning, former Chief Medical Officer at Roche, has extensive experience in drug development, having led the approval of 15 new medicines. Her role is expected to strengthen Cellarity's mission of transforming drug creation through innovative approaches that address complex diseases. The company's unique methodologies utilize high-resolution data and machine learning to enhance drug discovery. This strategic move is viewed positively for future product development.
Sana Biotechnology, Inc. (NASDAQ: SANA) announced that it will webcast its presentation at the BofA Securities 2022 Healthcare Conference on May 11, 2022, at 3:20 p.m. PT. The presentation will include a business overview by Steve Harr, President and CEO. Investors can access the live webcast on Sana's Investor Relations page, with a replay available for 30 days post-event. Sana focuses on engineered cells as medicines, aiming to repair genes and replace damaged cells, with operations in multiple U.S. locations.
Sana Biotechnology, Inc. (NASDAQ: SANA) announced the acceptance of five abstracts for presentation at the ASGCT 25th Annual Meeting in Washington, D.C. from May 16-19, 2022. The abstracts include two oral presentations on their hypoimmune platform, which aims to enable allogeneic cell transplants without the need for immunosuppression, and two poster presentations on their fusogen platform for targeted gene delivery. The company plans to file two Investigational New Drug applications within the year, focusing on translating their scientific advancements into viable therapeutics.
Tessera Therapeutics has secured over $300 million in Series C financing to advance its GENE WRITING technology aimed at curing genetic diseases. Investors include the Abu Dhabi Investment Authority and Alaska Permanent Fund Corporation. CEO Geoffrey von Maltzahn emphasizes the transformative potential of genetic medicine. The GENE WRITING platform enables precise modifications to DNA, unlocking new treatment possibilities for various conditions. Tessera's innovative approach positions it to potentially lead a new category in genetic medicine.
Sana Biotechnology, Inc. (NASDAQ: SANA) reported a strong cash position of $746.9 million as of December 31, 2021, up from $412.0 million in 2020, driven by a successful IPO. The company is advancing its pipeline, anticipating two IND applications in 2022 for its CAR T programs, SC291 and SG295. Additionally, Sana made significant progress in research and development, including partnerships for stem cells and gene editing. However, the net loss for 2021 was $355.9 million, or $2.14 per share, indicating ongoing financial challenges as they scale operations and clinical trials.
Sana Biotechnology, Inc. (NASDAQ: SANA) announced its participation in the 32nd Annual Oppenheimer Healthcare Conference, scheduled for March 16, 2022, at 6:20 a.m. PT. The event will feature a presentation by CEO Steve Harr, providing a business overview and updates. The webcast can be accessed on the company's Investor Relations page, with a replay available for 30 days post-conference. Sana is focused on developing engineered cell therapies aimed at changing disease treatment.
Sana Biotechnology, Inc. (NASDAQ: SANA) announced preclinical data from its hypoimmune T cell program, set to be presented at the 2022 AACR Annual Meeting from April 8-13 in New Orleans. The hypoimmune platform allows for allogeneic cell transplants without immunosuppression, demonstrating CAR T cells that evade immune response while maintaining anti-tumor efficacy. Sana plans to file investigational new drug applications for its CD19-expressing CAR T cell therapies, starting with SC291 in 2022 and SC276 in 2023.
Cellarity has announced key appointments to its executive team, enhancing its expertise in drug development. Laurens Kruidenier, Ph.D., joins as Chief Scientific Officer to lead drug platform evolution, while Anna O’Driscoll becomes Chief People Officer to drive talent development. Parul Doshi is appointed Senior VP, Head of Data and Software Engineering to bolster data infrastructure. These changes underscore Cellarity's commitment to advancing its drug creation process, particularly its unique approach that examines cellular changes underlying diseases, applicable across multiple therapeutic areas.
Sana Biotechnology (NASDAQ: SANA) has secured an exclusive worldwide license from the National Cancer Institute for the CD22 chimeric antigen receptor (CAR) technology. This agreement focuses on enhancing engineered T cell therapies for B cell malignancies, particularly addressing relapse challenges associated with current CD19-directed CAR therapies. With promising clinical data supporting the efficacy of CD22 CAR, Sana aims to improve outcomes for patients suffering from B cell malignancies, including non-Hodgkin lymphoma and acute lymphoblastic leukemia. Financial terms include upfront payments, milestone payments, and royalties on sales.